Economic evaluation of clopidogrel plus aspirin for secondary prevention of cardiovascular events in Canada for patients with established cardiovascular disease …

J Chen, C Shi, EM Mahoney, ES Dunn, S Rinfret… - Canadian Journal of …, 2011 - Elsevier
Abstract Background The Clopidogrel for High Atherothrombotic Risk and Ischemic
Stabilization, Management, and Avoidance (CHARISMA) trial found a statistically significant …
被引用次数：4 相关文章

Economic Evaluation of Clopidogrel Plus Aspirin for Secondary Prevention of Cardiovascular Events in Canada for Patients With Established Cardiovascular Disease …

J Chen, C Shi, EM Mahoney, ES Dunn, S Rinfret… - Canadian Journal of …, 2011 - infona.pl
The Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management,
and Avoidance (CHARISMA) trial found a statistically significant reduction in cardiovascular …

Economic evaluation of clopidogrel plus aspirin for secondary prevention of cardiovascular events in Canada for patients with established cardiovascular disease …

J Chen, C Shi, EM Mahoney, ES Dunn… - … Canadian Journal of …, 2011 - europepmc.org
Background The Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization,
Management, and Avoidance (CHARISMA) trial found a statistically significant reduction in …

Economic evaluation of clopidogrel plus aspirin for secondary prevention of cardiovascular events in Canada for patients with established cardiovascular disease …

J Chen, C Shi, EM Mahoney, ES Dunn, S Rinfret… - 2011 - pubmed.ncbi.nlm.nih.gov
Background The Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization,
Management, and Avoidance (CHARISMA) trial found a statistically significant reduction in …